4年，我们一起打败不可能

数据来源1：

1.Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA: a cancer journal for clinicians, 2024, 74(3): 229-263.

2.张希, 杨雷, 刘硕, 等. 2022年全球恶性肿瘤统计报告解读[J]. 中华肿瘤杂志, 2024, 46(7):710-721.

3.中国抗癌协会肝癌专业委员会. 中国肿瘤整合诊治指南（CACA）肝癌 V2.0. 2025：1125-1205.

4.Zeng H, Zheng R, Sun K, et al. Cancer survival statistics in China 2019–2021: a multicenter, population-based study[J]. Journal of the National Cancer Center, 2024, 4(3): 203-213.

Chang Z, Li M, Sun Z, et al. Clinical study on conversion therapy of hepatocellular carcinoma-summary and comparison of clinical data from a single center of consecutive four years[J]. BMC gastroenterology, 2024, 24(1): 369.

数据来源2：

1.Y-90 Resin Microspheres Receive FDA Approval for the Treatment of Unresectable HCC. https://ascopost.com/news/july-2025/y-90-resin-microspheres-receive-fda-approval-for-the-treatment-of-unresectable-hcc/

2.Mahvash A, Chartier S, Turco M, et al. A prospective, multicenter, open-label, single-arm clinical trial design to evaluate the safety and efficacy of 90Y resin microspheres for the treatment of unresectable HCC: the DOORwaY90 (Duration Of Objective Response with arterial Ytrrium-90) study[J]. BMC gastroenterology, 2022, 22(1): 151.

3.DOORwaY90研究：钇-90树脂微球获FDA批准，开启不可切除肝癌治疗新纪元.https://mp.weixin.qq.com/s/lBd_5JvddYsVmpz_Yjm2tw

4.Arepally A, Tully M, Stein L, et al. Frequency of complete pathological necrosis in HCC of explanted livers: radioembolization with resin vs drug-eluting beads with doxorubicin[J]. Journal of Vascular and Interventional Radiology, 2017, 2(28): S75.）